Background and Purpose-The purpose of this study was to determine the safety and efficacy of intravenous recombinant tissue-type plasminogen activator (0.6 mg/kg alteplase) within 3 hours of stroke onset in Japanese patients outside the indications in the European license. 
Patients were derived from the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) rtPA Registry. 2 Patient eligibility for alteplase was determined based on the Japanese guideline 3 stating that patients Ն75 years old, those with NIHSS score Ն23, those with a history of prior stroke, and those with poorly controlled diabetes are to be carefully considered but not excluded. Other exclusion criteria are almost identical between the European and Japanese indications. Each patient received alteplase (0.6 mg/kg) intravenously with 10% given as a bolus within 3 hours of stroke onset and the remainder delivered through continuous intravenous infusion over 1 hour. Patients not meeting the inclusion criteria of the European license were categorized into the OUT group and those who did were categorized into the IN group.
Outcomes included: any and symptomatic intracerebral hemorrhage (ICH) within the initial 36 hours, complete independence (modified Rankin Scale score 0 -1), unfavorable outcome (modified Rankin Scale score 5-6) at 3 months, and death within 3 months. Symptomatic ICH was defined as that associated with neurological deterioration corresponding to an increase of Ն4 points from the baseline NIHSS score.
To evaluate the independent effect of the OUT group and each exclusion criterion on the clinical outcomes, a multivariate logistic regression model was estimated adjusting for sex, hypertension, dyslipidemia, atrial fibrillation, onset-to-treatment time, Alberta Stroke Programme Early CT Score, and internal carotid artery occlusion. The model was adjusted for: patients Ͼ80 years using NIHSS score, prior stroke, and diabetes; patients with NIHSS score Ն25, using age, prior stroke, and diabetes; and patients with prior stroke plus diabetes using age and NIHSS score.
Results
Of the 600 patients, 178 (85 men; age, 81.7Ϯ8.6 years) were categorized into the OUT group and the remaining 422 (292 men; 67.7Ϯ10.5 years) into the IN group. A higher percentage of patients in the OUT group were female, older, hypertensive, diabetic, and had higher initial NIHSS scores and internal carotid artery occlusion compared with the IN group (Supplemental Table I ; http://stroke.ahajournals.org). Of the OUT group, 129 patients were Ͼ80 years old, 40 had severe stroke with an NIHSS score Ն25, and 25 had prior stroke plus diabetes. After multivariate adjustment, any ICH was less common in patients in the OUT group than those in the IN group, but the frequency of symptomatic ICH did not differ significantly between the groups. Unfavorable outcome and death were more common in the OUT group than in the IN group and in patients with a NIHSS score Ն25 compared with those Ͻ25. Unfavorable outcome was also more common in patients Ͼ80 years than those Յ80 years (Table) . The Figure shows the distribution of patients and their modified Rankin Scale scores at 3 months.
Discussion
More than 25% of ischemic strokes occur in patients Ն80 years old in Japan. 4 Advanced age was reported to be a strong predictor of poor outcomes and mortality independent of other clinical characteristics. 5 Randomized trials on rtPA did not include a sufficient number of patients with advanced age. 6 -9 In the National Institute of Neurological Disorders and Stroke trial, 6 rtPA treatment was associated with increased likelihood of favorable outcome 3 months after stroke even in 49 patients aged Ͼ75 years with a NIHSS score Ͼ20 as compared with the placebo group. Risk of symptomatic ICH after thrombolysis did not increase, although clinical outcomes were worse in patients Ͼ80 years old as compared with younger patients in several studies. 10 -13 An adjusted, controlled comparison based on 3472 patients Ͼ80 years old showed a better distribution of the modified Rankin Scale in thrombolysis patients than nonthrombolysis patients. 14 In this study, 0.6 mg/kg of alteplase may have caused the relatively small number of symptomatic ICH both in patients older than and Յ80 years old.
Diabetes mellitus was independently associated with symptomatic ICH after standard-dose rtPA therapy. 15 Infrequent development of ICH in our cohort and exclusion of patients with premorbid modified Rankin Scale Ն2 from the outcome analysis might weaken the impact of prior stroke plus diabetes on outcomes in this study. The small number of patients with prior stroke plus diabetes might also affect the statistical power.
This was not a randomized controlled study, subgroups were small, and physicians used judgment in selecting patients, all of which limit this study and introduce potential for error. In addition, data for patients with stroke who did not undergo thrombolysis were not collected and a comparison of patients with and without thrombolysis was not done.
In conclusion, 3-month outcomes after low-dose rtPA in patients outside the European indications were less favorable compared with those included in the indications. Low-dose intravenous rtPA therapy may be safely administered to patients outside the European indications without an increase of ICH by careful selection of patients. Patients with prior stroke and concomitant diabetes seem to be appropriate candidates for rtPA therapy.
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